Compare · MTD vs TXG
MTD vs TXG
Side-by-side comparison of Mettler-Toledo International Inc. (MTD) and 10x Genomics Inc. (TXG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MTD and TXG operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- MTD is the larger of the two at $28.10B, about 3.3x TXG ($8.43B).
- TXG has been more active in the news (8 items in the past 4 weeks vs 7 for MTD).
- TXG has more recent analyst coverage (25 ratings vs 23 for MTD).
- Company
- Mettler-Toledo International Inc.
- 10x Genomics Inc.
- Price
- -
- -
- Market cap
- $28.10B
- $8.43B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1997
- 2019
- News (4w)
- 7
- 8
- Recent ratings
- 23
- 25
Mettler-Toledo International Inc.
Mettler-Toledo International Inc. manufactures and supplies precision instruments and services worldwide. It operates in five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company offers weighing instruments for laboratory, industrial, packaging, logistics, and food retailing applications; various related analytical instruments and automated chemistry solutions used in drug and chemical compound discovery and development; metal detection and other end-of-line product inspection systems used in production and packaging for food processing and packaging, pharmaceutical, packaged consumer goods, and other industries; and solutions that are used in various process analytics applications. Its laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform. The company's industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, and product inspection systems. Its retail weighing solutions consist of networked scales and software, and stand-alone scales for handling fresh goods, such as meats, vegetables, fruits, and cheeses. The company serves the life science industry, and independent research organizations; food and beverage producers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community. It markets its products through its direct sales force and indirect distribution channels. The company was incorporated in 1991 and is based in Columbus, Ohio.
10x Genomics Inc.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Latest MTD
- Director Salice Thomas P exercised 417 shares at a strike of $397.95 and sold $600,651 worth of shares (417 units at $1,440.41) (SEC Form 4)
- Director Salice Thomas P exercised 415 shares at a strike of $397.95 and sold $599,517 worth of shares (415 units at $1,444.62) (SEC Form 4)
- Head of Process Analytics Keller Gerry exercised 240 shares at a strike of $720.81 and sold $342,514 worth of shares (240 units at $1,427.14) (SEC Form 4)
- Chief Financial Officer Vadala Shawn exercised 2,240 shares at a strike of $595.31 and sold $3,207,680 worth of shares (2,240 units at $1,432.00) (SEC Form 4)
- SEC Form 3 filed by new insider Shuman-Fabbri Natalia
- Mettler-Toledo International Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Natalia Shuman Joins Mettler Toledo Board of Directors
- SEC Form 10-Q filed by Mettler-Toledo International Inc.
- Mettler-Toledo International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Mettler-Toledo International Inc. Reports Second Quarter 2026 Results
Latest TXG
- SEC Form 144 filed by 10x Genomics Inc.
- Chief Executive Officer Saxonov Serge gifted 4,000 shares, decreasing direct ownership by 0.36% to 1,104,380 units (SEC Form 4)
- Director Teichmann Sarah A. sold $432,279 worth of shares (7,551 units at $57.25) as part of a pre-agreed trading plan, decreasing direct ownership by 21% to 28,058 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.
- Director Stuelpnagel John R sold $1,155,055 worth of shares (20,000 units at $57.75), decreasing direct ownership by 5% to 348,436 units (SEC Form 4)
- SEC Form 144 filed by 10x Genomics Inc.
- 10x Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- 10x Genomics Reports Second Quarter 2026 Financial Results
- 10x Genomics and Lausanne University Hospital Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies for Cancer Care
- 10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026